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ABSTRACT  
The development of scaffolds that combine the delivery of drugs with the physical support provided 
by electrospun fibres holds great potential in the field of nerve regeneration. Here it is proposed the 
incorporation of ibuprofen, a well-known non-steroidal anti-inflammatory drug, in electrospun fibres 
of the statistical copolymer poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] to serve as 
a drug delivery system to enhance axonal regeneration in the context of a spinal cord lesion, by 
limiting the inflammatory response. P(TMC-CL) fibres were electrospun from mixtures of 
dichloromethane (DCM) and dimethylformamide (DMF). The solvent mixture applied influenced 
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fibre morphology, as well as mean fibre diameter, which decreased as the DMF content in solution 
increased. Ibuprofen-loaded fibres were prepared from P(TMC-CL) solutions containing 5% 
ibuprofen (w/w of polymer). Increasing drug content to 10% led to jet instability, resulting in the 
formation of a less homogeneous fibrous mesh. Under the optimized conditions, drug-loading 
efficiency was above 80%. Confocal Raman mapping showed no preferential distribution of 
ibuprofen in P(TMC-CL) fibres. Under physiological conditions ibuprofen was released in 24 h. The 
release process being diffusion-dependent for fibres prepared from DCM solutions, in contrast to 
fibres prepared from DCM-DMF mixtures where burst release occurred. The biological activity of the 
drug released was demonstrated using human-derived macrophages. The release of prostaglandin 
E2 to the cell culture medium was reduced when cells were incubated with ibuprofen-loaded P(TMC-
CL) fibres, confirming the biological significance of the drug delivery strategy presented. Overall, this 
study constitutes an important contribution to the design of a P(TMC-CL)-based nerve conduit with 
anti-inflammatory properties. 
Keywords confocal Raman microscopy; drug delivery; electrospinning; ibuprofen; 
inflammation; nerve guide 
1. INTRODUCTION  
The first patent on electrospinning dates from 1934 by Formhals (1934). More recently, the technique 
was ‘reinvented’, becoming very popular for the preparation of tissue engineering scaffolds (Martins 
et al., 2007; Agarwal et al., 2009). Electrospinning allows the fabrication of nanofibrous scaffolds that 
can emulate the extracellular matrix, providing a biomimetic environment for cell growth, 
polarization and differentiation. In addition, a number of parameters in the electrospinning setup can 
be adjusted in order to modulate fibre diameter and orientation, as well as scaffold size and shape. 
The possibility of preparing aligned fibres has been especially explored in the context of nerve repair 
(Xie et al., 2010; Lee and Arinzeh, 2011). Previous reports show that neurons align their cellular 
processes in the direction of electrospun fibres in vitro (Corey et al., 2007; Yao et al., 2009). A similar 
outcome was observed in vivo, both in the peripheral (Yu et al., 2011; Jiang et al., 2012) and in the 
central nervous system (Hurtado et al., 2011). Electrospun scaffolds can also serve as drug delivery 
devices. Owing to the versatility of the electrospinning technique, different types of molecules can 
be incorporated in fibres. For nerve regeneration applications, fibres have been loaded with 
neurotrophins (Chew et al., 2005; Liu et al., 2012) or drugs, like 6‐aminonicotinamide, known to limit 
astrocyte proliferation (Schaub and Gilbert, 2011). To promote central nervous system regeneration, 
the combination of nanofibrous scaffolds with molecules that can locally hinder the inhibitory 
environment after a lesion is of particular interest (Liu et al., 2012).  
Inflammation is one of the secondary events activated after a central nervous system lesion and one 
of the most relevant targets in nerve regeneration strategies (Thuret et al., 2006; Fitch and Silver, 
2008). Although the role of inflammation in central nervous system regeneration is currently an issue 
of active debate (Chan, 2008; Schwartz et al., 2009), the results of clinical trials that involved 
assessment of drugs with described anti‐inflammatory properties, namely the antibiotic minocycline 
(Casha et al., 2012), support strategies targeting the modulation of the inflammatory response.  
This report proposes the incorporation of ibuprofen in electrospun fibres as a drug delivery system to 
enhance axonal regeneration in the context of a spinal cord lesion by limiting the inflammatory 
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response. Ibuprofen is a non‐steroidal anti‐inflammatory drug and its action is attributed to the 
inhibitory effect on cyclooxygenase (COX). This enzyme is responsible for the conversion of 
arachidonic acid in prostaglandins, the latter being associated with pain, fever and acute 
inflammatory reaction (Mitchell et al., 1993; Rainsford, 2009). In addition to the classical view of the 
action of ibuprofen, the release of prostaglandin E2 (PGE2) has been more recently associated with 
neuropathic pain after spinal cord injury (Zhao et al., 2007). Consequently, targeting the COX 
pathway is currently indicated as a new avenue to treat this condition (Ma et al., 2012), providing 
added value to the strategy proposed in this manuscript.  
Poly(trimethylene carbonate‐co‐ε‐caprolactone) [P(TMC‐CL)] is a biodegradable elastomer 
previously studied in the field of nerve regeneration research. The polymer possesses mechanical 
properties and a degradation profile appropriate to serve as nerve conduit (Pêgo et al., 2001, 2003) 
and it has shown to be able to support peripheral nerve regeneration in vivo (Vleggeert‐Lankamp et 
al., 2008). In the present work, it is proposed that P(TMC‐CL) serve as polymeric matrix for the 
delivery of ibuprofen. The optimization of electrospun P(TMC‐CL) fibre preparation, the 
incorporation of the drug and its release profile and bioactivity are investigated.  
2 Materials and methods 
2.1 Polymer synthesis 
Poly(trimethylene carbonate‐co‐ε‐caprolactone) was prepared by ring‐opening polymerization as 
previously described (Pêgo et al., 2001). In brief, ε‐caprolactone (CL) (Merck, Darmstadt, Germany) 
was dried overnight (calcium hydride; Sigma‐Aldrich Química, Sintra, Portugal) and distilled before 
the polymerization with trimethylene carbonate (TMC, used as received from Boehringer Ingelheim, 
Ingelheim am Rhein, Germany). Polymerization was carried out in evacuated and sealed glass 
ampoules using stannous octoate (Sigma‐Aldrich) as catalyst (2 × 10–4 mol per mol of monomer). 
After 3 days of reaction at 130 °C the polymer obtained was purified by dissolution in chloroform 
(BDH‐Prolabo, Carnaxide, Portugal) and subsequent precipitation into a tenfold volume of ethanol 
(96%, v/v; AGA, Prior Velho, Portugal). The chemical composition of the copolymer was assessed by 
1H nuclear magnetic resonance (NMR) and found to contain 11% mol of TMC, which is in accord with 
the monomer ratio charged (10% mol TMC). The molecular weight of the obtained polymer was 
determined by size exclusion chromatography using chloroform as the mobile phase. The average 
molecular weight was found to be 8.2 × 104 g/mol and the polydispersity index was 1.61.  
2.2 P(TMC‐CL) and ibuprofen‐loaded P(TMC‐CL) fibre preparation 
by electrospinning 
Initially, a range of electrospinning parameters was assessed. The parameters tested included 
polymer concentration in the electrospun solution (6–10%, w/v), polymer solvent [dichloromethane 
(DCM; Merck), chloroform (Sigma‐Aldrich) and N,N‐dimethylformamide (DMF), Merck)], flow rate 
(0.1–1.5 ml/h), and electric field applied (0.5–1 kV /cm). Based on the morphology of the fibres 
obtained (data not shown) the selected conditions for the subsequent experiments were: P(TMC‐CL) 
solutions (10%, w/v) dispensed at a flow rate of 1 ml/h using a syringe pump (Ugo Basile, Italy); an 
electric field (Gamma High Voltage source; Ormond Beach, FL, USA) of 1 kV/cm applied between the 
spinneret (inner diameter 0.8 mm) and a flat copper plate (15 × 15 cm) separated by 14 cm; DCM and 
DMF mixtures used as solvent at the volume ratios of 1:0, 6:1, 3:1 and 1:1. Fibres were collected into 
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an aluminium foil for 1–1.5 h. After vacuum drying (vacuum oven, Raypa, Barcelona, Spain) for 24 h, 
14 mm discs were punched out from the electrospun membranes and stored at room temperature 
(20‐25 °C) until further use.  
Ibuprofen‐loaded fibres were obtained by adding 5% and 10% of ibuprofen powder (w/w of polymer) 
to the polymer solution 5 h before electrospinning. Pharmaceutical grade ibuprofen (purity > 99%) 
was kindly supplied by Sérgio Simões (Bluepharma, Coimbra, Portugal). 
2.3 Fibre characterization 
2.3.1 Fibre morphology 
Fibre morphology was analysed by scanning electron microscopy (SEM). A low vacuum (5 kV) 
Phenom™ G2 (Phenom‐World, Eindhoven, the Netherlands) and a Quanta 400FEG ESEM (FEI, 
Eindhoven, the Netherlands) microscopes were used. Fibre diameter was quantified from SEM 
micrographs using image analysis software (Image J, version 1.39; NIH, Bethesda, MD, USA). Fibre 
mean diameter and fibre diameter distribution were calculated from at least 100 measurements from 
three independent samples. 
2.3.2 Drug loading efficiency 
1H NMR spectroscopy was used in order to quantify ibuprofen in the P(TMC‐CL) electrospun meshes. 
The analyses were performed in an AVANCE III 400 spectrometer (Bruker Corporation, Barcelona, 
Spain), operating at 400 MHz. The 1H chemical shifts were internally referenced to the 
tetramethylsilane (TMS; Eurisotop, Saint‐Aubin, France) signal (0.00 ppm) for spectra recorded in 
CDCl3 (Sigma‐Aldrich). Ibuprofen‐loaded P(TMC‐CL) fibres were dissolved in CDCl3 before analysis. 
Characteristic peaks from ibuprofen and P(TMC‐CL) were used to identify both species. The drug 
loading efficiency was calculated from the ratio between the area of the signal at δ = 2.45 ppm 
corresponding to the CH2 group of ibuprofen (2H), and the area of the peak corresponding to the 
resonance of the α‐methylene (δ = 2.30, 2H, CH2) of polymeric caprolactone.  
2.3.3 Ibuprofen distribution in P(TMC‐CL) fibres 
Ibuprofen powder and P(TMC‐CL) fibres prepared from 1:0 and 3:1 DCM–DMF mixtures with and 
without ibuprofen incorporated (5%, w/w, of polymer) were analysed using Fourier transform 
infrared spectroscopy (FTIR) and confocal Raman microscopy. 
The FTIR characterization was performed using a Perkin Elmer 2000 spectrometer (Perkin Elmer, 
Waltham, MA, USA) and an attenuated total reflectance (ATR) accessory (SplitPea™; Harrick 
Scientific, Pleasantville, NY USA), provided with a silicon internal reflection element and configured 
for external reflectance mode, where the spectra were acquired from a 200 µm diameter sampling 
area. A nitrogen purge was performed before each experiment. All samples were run at a spectral 
resolution of 4/cm and 200 scans were accumulated in order to obtain a high signal‐to‐noise level. 
The band at 1675–1775/cm was deconvoluted by applying the derivative and curve fitting algorithms 
using peakfit from AISN Software (Florence, Oregon, USA). Initial peak positions were obtained from 
second derivative spectra of the raw data. A Lorentzian band‐shape was used to fit the contours.  
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Confocal Raman microscopy analyses were performed using a LabRAM HR 800 confocal Raman 
microscope system (Horiba Jobin Yvon, Lille, France) comprising a spectrometer and a fully 
integrated Olympus BX41 confocal microscope (Olympus Iberia, S.A.U., Lisboa, Portugal). Raman 
spectra were generated using a 514 nm laser diode as excitation source, focused on the sample with 
a × 100 objective, a confocal hole of 100 µm and an exposure time of 100 s. For the experimental 
setup used, the spatial resolution is between 0.5 µm and 1 µm. The scattered light was dispersed by 
a grating with 1800 lines/mm (Jobin‐Yvon) at 4/cm spectral resolution. Spectral analysis was carried 
out using labspec5 software (Horiba Jobin Yvon). Imaging experiments on fibres were performed by 
scanning the laser beam over the region of interest and accumulating a full Raman spectrum at each 
pixel. Raman images were constructed by plotting the integrated intensity of the vibrational bands 
of interest as a function of position. For these experiments, fibres with a diameter > 2 µm were 
selected and step size for data acquisition was approximately 0.6 µm. The spectral range measured 
was 1400–1800/cm and the mapping area varied according to the fibre dimension.  
2.4 Drug‐release studies 
The amount of ibuprofen released from the electrospun P(TMC‐CL) fibres was evaluated as follows. 
Samples loaded with 5% of ibuprofen (w/w of polymer) were incubated at 37 °C and 120 rpm (Orbital 
Shaker Oven; IKA, Staufen, Germany) in phosphate buffered saline (PBS) at the final concentration 
of 5 mg/ml (mass of fibres/volume of PBS). At defined time‐points (0.5, 1, 2, 4, 6, 8, and 24 h) the 
releasing medium was refreshed. Ultraviolet/visible spectroscopy (UV/Vis) at 230 nm (SynergyMx; 
Biotek, Carnaxide, Portugal) was used to monitor the amount of ibuprofen released. Values were 
interpolated from an ibuprofen calibration curve (see the Supporting Information, Figure S4). 
Cumulative release was calculated relative to the maximum loading of 5% (w/w of polymer). The drug 
release kinetics was analysed using the Higuchi simplified model:  
Mt/M∞ = k√t                                                    (1) 
Where Mt/M∞ epresents cumulative ibuprofen release, t is time of incubation and k is a constant 
reflecting the design variables of the system (Siepmann and Peppas, 2001).  
2.5 Biological effect of ibuprofen on human macrophages 
2.5.1 Peripheral blood‐derived monocyte isolation 
Human peripheral blood‐derived monocytes were isolated from Buffy coats (kindly donated by 
Instituto Português do Sangue, Porto, Portugal) by negative selection using Rosettesep™ (StemCell 
Technologies, Grenoble, France) as previously described (Oliveira et al., 2012). A day after isolation, 
adherent cells were collected applying a 5 mm solution of ethylenediamine tetraacetic acid (EDTA; 
BDH‐Prolabo) and reseeded on glass coverslips at a cell density of 1.25 × 105 cells/cm2. The cell 
population contained > 70% of CD14 positive cells and no contamination by CD3‐positive T 
lymphocytes, as determined by flow cytometry (Oliveira et al., 2012). Cells were allowed to 
differentiate in RPMI medium (Gibco, Life technologies S.A., Madrid, Spain) supplemented with 10% 
of heat‐inactivated (56 °C, 30 min) fetal bovine serum (Lonza, Barcelona, Spain) for additional 8 days. 
Ten days after isolation, monocyte‐derived macrophages were stimulated with 10 ng/ml 
lipopolysaccharide (LPS; Sigma) for 72 h. Specific cell treatments were performed after LPS 
activation.  
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2.5.2 Cell culture 
The effect of ibuprofen on macrophage metabolic activity was assessed by means of a resazurin‐
based assay. In brief, different ibuprofen solutions in ethanol–water mixtures (7:3) were prepared and 
added (5 µl) to the cell culture media (500 µl) in order to obtain a final drug concentration ranging 
from 0.001 mg/ml to 1 mg/ml. Cell metabolic activity was evaluated at 24 h and 72 h after treatment. 
At the defined time‐point cells were incubated (4 h, 37 °C) with a resazurin (Sigma‐Aldrich) solution 
(0.1 mg/ml, in PBS) and the fluorescence (λex = 530 nm, λem = 590 nm) in the cell culture medium was 
measured (SynergyMx; Biotek). Results are represented as percentage of cell viability relative to cells 
treated with equal volume of the ibuprofen solvent (5 µl).  
In order to evaluate the bioactivity of ibuprofen released from P(TMC‐CL) electrospun fibres, fibre 
discs (14 mm) were incubated with macrophages for 72 h. The fibres tested were prepared from 1:0 
DCM–DMF solutions loaded with 5% ibuprofen (w/w of polymer). The punched discs weighed 
between 0.9 mg and 3 mg. Fibre sterilization was performed by irradiating (gamma rays, 25 kGy, 60Co 
source) samples previously packed under vacuum. Fibre discs were suspended in the well without 
direct contact with the cells. Macrophages treated with ibuprofen in the medium (final concentration 
0.1 mg/ml), as well as cells cultured in presence of unloaded P(TMC‐CL) fibres, were used as control.  
2.5.3 Immunofluorescence 
To analyse cell morphology, macrophages were fixed with 4% (w/v) paraformaldehyde (Merck) and 
immunostained for α‐tubulin and F‐actin as follows. Cell external fluorescence was quenched by 
treating the cells with 50 mm NH4Cl for 10 min. Subsequently, cells were permeabilized with 0.1% 
(v/v) Triton X‐100 (in PBS) for 5 min. After washing with PBS, cells were incubated with 5% (w/v) 
bovine serum albumin (BSA; Sigma‐Aldrich) in PBS for 30 min and, thereafter, incubated with the 
primary antibody mouse anti‐α‐tubulin (1:4000; Sigma‐Aldrich) for 1 h. Subsequently, cells were 
thoroughly washed and incubated with Alexa Fluor 594 goat anti‐mouse IgG (1:1000; Invitrogen, Life 
technologies Madrid, Spain) for 45 min. F‐actin was stained for 15 min using 5 µm Phalloidin‐FITC 
(Sigma‐Aldrich). Cells were washed with PBS and mounted on Vectashield with 4′,6‐diamidino‐2‐
phenylindole (DAPI; Vector Laboratories, Peterborough, UK). Samples were observed under an 
inverted fluorescence microscope (Axiovert 200; Zeiss, Oberkochen, Germany).  
2.5.4 PGE2 and quantification of cytokines  
At the defined time‐point (72 h after treatment), cell culture supernatants were collected and, after 
centrifugation (16000 g, 4 °C, 10 min) to remove cell debris, stored at –20 °C for posterior analysis. 
The concentration in the cell culture supernatant of PGE2 (Cayman Chemical, Ann Arbor, MI, USA), 
interleukin 6 (IL‐6), IL‐10 and tumour necrosis factor‐α (TNFα) were quantified by enzyme‐linked 
immunosorbent assay (ELISA; Biolegend, San Diego, CA, USA) following the manufacturer's 
instructions. Results are presented normalized for the total protein content in the cell culture 
medium, as determined by the DC protein assay (Bio‐Rad, Amadora, Portugal).  
2.6 Statistical analysis 
Statistical analysis was performed using prism 5.0 software (GraphPad, La Jolla, CA, USA). Statistical 
differences between two groups were calculated applying a t‐test when analysing results from PGE2 
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and release of cytokines. Mean fibre diameters obtained when using different solvent combinations 
loaded or unloaded with ibuprofen were analysed using non‐parametric Kruskal–Wallis test and 
Bonferroni correction for multiple comparisons. A p‐value lower than 0.05 was considered 
statistically significant.  
3 Results 
3.1 Characterization of P(TMC‐CL) and ibuprofen‐loaded P(TMC‐CL) 
fibres 
3.1.1 Fibre morphology 
The influence of solvent composition on P(TMC‐CL) fibre morphology was evaluated by testing 
different DCM–DMF mixtures (Figure 1, Table 1). Fibres prepared from 1:0 DCM–DMF solutions 
showed a broad diameter distribution. Improved homogeneity of the fibres was observed when 
increasing the DMF fraction in solution, as shown by the narrowing of the fibre diameter distribution 
(Figure 1). The fibre mean diameter was found to be 1.09 ± 0.10 µm for fibres prepared from 1:0 
DCM–DMF solutions, decreasing to 0.48 ± 0.03 µm for fibres prepared from 1:1 DCM–DMF solutions 
(Table 1).  
Ibuprofen‐loaded P(TMC‐CL) fibres were prepared by adding 5 % and 10 % of the drug (w/w of 
polymer) to the polymer solution before electrospinning. Electrospinning parameters applied were 
the same as those optimized for the preparation of the non‐loaded fibres. When 5% of ibuprofen 
(w/w of polymer) was added to the P(TMC‐CL) solution, smaller fibres were formed, as indicated by 
the decrease in mean fibre diameter in comparison with unloaded fibres (Table 1). When analysing 
the effect of the solvent composition on the morphology of 5% ibuprofen‐loaded fibres, under the 
conditions tested, fibres prepared from 1:1 DCM–DMF solutions fused (Figure 2). For this reason, a 
1:1 DCM–DMF solutions was not tested for 10% ibuprofen‐loaded fibres. No significant differences in 
terms of mean fibre diameter were detected when comparing loaded fibres prepared from 1:0, 6:1 
and 3:1 DCM–DMF solutions. However, in terms of fibre diameter distribution a higher percentage of 
bigger fibres (> 3 µm) were formed from 1:0 DCM–DMF solutions (Figure 2). When fibres were 
prepared from solutions with 10% ibuprofen (w/w of polymer), the high drug content led to jet 
instability, resulting in a less homogeneous fibre mesh. Under these conditions a tendency towards 
the formation of defects and large‐diameter fibres was observed, as indicated by the fibre diameter 
distribution graphs (Figure 2), albeit the mean fibre diameter was not remarkably affected (Table 1). 
For fibres prepared from 3:1 DCM–DMF solutions, in particular, fusion of the deposited fibres was also 
observed. 
3.1.2 Drug loading and distribution 
The chemical composition of ibuprofen‐loaded P(TMC‐CL) fibres was analysed by means of three 
spectroscopic techniques: 1H NMR, ATR‐FTIR and Raman.  
By 1H NMR spectroscopy, ibuprofen was clearly distinguished from P(TMC‐CL) signals (see the 
Supporting information, Figure S1). The amount of drug relative to the polymer was quantified using 
this technique. It was found that in the 5% ibuprofen (w/w of polymer) loaded P(TMC‐CL) fibres the 
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actual loading was 4.21 ± 0.02 % (w/w of polymer; n = 3), corresponding to a loading efficiency of over 
80%.  
As NMR provides information about the bulk chemical composition of the prepared samples, to 
obtain complementary chemical characterization of the fibres, these were also analysed by ATR‐
FTIR. Figure 3A shows the spectra of ibuprofen‐loaded P(TMC‐CL) fibres prepared from 1:0 DMC‐
DMF solution, unloaded fibres and ibuprofen powder. The most intense bands of ibuprofen are 
located at 2955, 1721 and 1231/cm, being assigned to CH3 asymmetric stretching, C = O stretching 
and C–C stretching, respectively (see full FTIR spectra in Figure S2). These bands cannot be 
distinguished in the ibuprofen‐loaded fibres because of overlapping with the polymer signals. 
Although weak, the band corresponding to the aromatic C = C stretching vibration of ibuprofen 
(1509/cm) can be identified in the ibuprofen‐loaded P(TMC‐CL) fibre spectrum, confirming the 
presence of the drug in the fibres (Figure 3A). In order to identify the presence of subtle spectral 
changes in the region of the most intense bands of ibuprofen and P(TMC‐CL) (1670–1800/cm) a 
second derivatization and curve fitting of the raw data was performed. Figure 3AI,II) shows that the 
number of bands in that particular zone of the spectrum increases in the loaded polymer samples 
further supporting the presence of ibuprofen in the fibres. Analysis of the ibuprofen‐loaded P(TMC‐
CL) spectrum compared with those of P(TMC‐CL) and ibuprofen showed no differences other than 
the characteristic bands of the starting materials, suggesting that no chemical interaction between 
ibuprofen and the polymer occurred. ATR‐FTIR analysis of P(TMC‐CL) fibres prepared from 3:1 DCM–
DMF solutions was also performed and similar spectra were obtained.  
As a complementary technique to FTIR P(TMC‐CL), individual fibres were analysed by confocal 
Raman spectroscopy. By using this technique it was possible to identify the C–C stretching (1610/cm) 
on the fingerprint region of ibuprofen (Figure 3B). The presence of this clear marker band allowed the 
use of Raman mapping to determine and compare the spatial distribution of ibuprofen in P(TMC‐CL) 
fibres prepared with 1:0 and 3:1 DCM–DMF solutions. Data was acquired on an area of the fibre as 
shown in Figure 3CI,DI). Mapping was performed by rationing the ibuprofen fingerprint region to the 
background signal in two different spectral regions: 1510–1525/cm and 1645–1665/cm. Regions with 
high concentration of ibuprofen are depicted in bright green, while regions with low ibuprofen 
concentration are shown in black (see Figure 3E). Although drug distribution is not completely 
homogeneous, results show no preferential distribution of the drug at fibre edges or in the centre for 
both ibuprofen‐containing fibres prepared from 1:0 and 3:1 DCM–DMF P(TMC‐CL) solutions (Figure 3 
(CII,DII).  
3.2 Drug‐release studies 
The release of ibuprofen from P(TMC‐CL) fibres was evaluated in PBS at 37 °C, to mimic physiological 
conditions. The amount of ibuprofen released was interpolated from a calibration curve and the 
percentage of cumulative release was calculated relative to the maximum loading of 5% (w/w of 
polymer). 
Under the experimental conditions tested, ibuprofen was released from the P(TMC‐CL) fibres within 
the first 24 h of incubation in PBS (37 °C), independently of the solvent mixture used for fibre 
preparation. None, or residual amounts of ibuprofen were detected in the releasing medium when 
loaded fibres were incubated for longer periods (data not shown). In the case of fibres prepared from 
6:1 and 3:1 DCM–DMF solutions, a burst release appeared to occur (Figure 4B,C). In contrast, the 
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release kinetics of ibuprofen from fibres prepared in 1:0 DCM–DMF was slower, suggesting time‐
dependency (Figure 4A). Analysing ibuprofen release using the Higuchi model it was found that the 
release profile of ibuprofen from P(TMC‐CL) fibres prepared from 1:0 DCM–DMF solutions fitted 
better in the model, indicating that the release is diffusion dependent for the first 8 h of incubation in 
PBS (see fitting curve in Figure S5). Observation of the fibres after the drug release experiments 
showed that fibre morphology was maintained upon drug release (Figure S6).  
3.3 Biological evaluation 
Ibuprofen anti‐inflammatory properties have been associated to its inhibitory action on COX 
(Mitchell et al., 1993). This enzyme is responsible for the formation of prostaglandins (such as PGE2) 
from arachidonic acid, and is related with the inflammatory response (for a review see Rainsford, 
2009). To ensure that the ibuprofen incorporated into the P(TMC‐CL) fibres exerted its biological 
activity, the release of cytokines and PGE2 by monocyte‐derived human macrophages was quantified 
after incubating the cells with the fibers or soluble ibuprofen (positive control). Taking advantage of 
the fact that P(TMC‐CL) density is similar to water density and consequently the discs hang in cell 
culture medium, the fibres were incubated without direct contact with the adhered cells. This set up 
made it possible to distinguish the effect of the drug from any effect triggered by the polymer 
surface, as macrophage response and differentiation is affected by surface chemistry (Brodbeck et 
al., 2002), and by its topography (Cao et al., 2010). In this study the aim was to discern the effect of 
the released drug regardless of cell–material interaction.  
3.3.1 Effect of ibuprofen on macrophage cell viability and morphology 
To assess ibuprofen cytotoxic profile on monocyte‐derived human macrophages, the drug was added 
in its soluble form to the cell culture medium to a final concentration ranging from 0.001–1 mg /ml. 
Ibuprofen solvent (ethanol 70% v/v) was also applied as a negative control. The graph presented in 
Figure 5A indicates that, at the highest concentration tested (1 mg/ml), ibuprofen was toxic for 
macrophages, significantly reducing cell viability (< 10%). Similar results were obtained when cell 
metabolic activity was assessed 24 h post‐treatment (data not shown). Taking into consideration 
these results, 0.1 mg/ml soluble of ibuprofen was applied in the following experiments as control.  
The effect of ibuprofen‐loaded P(TMC‐CL) fibres on macrophage morphology was investigated by 
observing the distribution pattern of cytoskeleton proteins (α‐tubulin and F‐actin). Therefore, human 
primary macrophages were incubated for 72 h with soluble ibuprofen at a final concentration of 
0.1 mg/ml, with ethanol (70% v/v, ibuprofen solvent), with P(TMC‐CL) fibres or with ibuprofen‐loaded 
P(TMC‐CL) fibres. In all the experimental conditions tested macrophages showed evidence of 
heterogeneous cell morphology, with round‐shaped cells and F‐actin staining concentrated at the 
cell periphery in podosome‐like structures, and elongated cells with less intense and peripheral F‐
actin staining. In contrast, α‐tubulin staining was always homogeneously distributed along the cell 
body and according the cell axis (Figure 5). No significant differences in terms of macrophage 
morphology were observed between the different experimental conditions.  
3.3.2 Anti‐inflammatory properties of ibuprofen‐loaded P(TMC‐CL) fibres 
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To assess if the ibuprofen released from ibuprofen‐loaded P(TMC‐CL) electrospun fibres is bioactive, 
the concentration of soluble PGE2 produced by exposed macrophages was quantified in the cell 
culture supernatants after 72 h of incubation.  
The results (Figure 6) indicate that when ibuprofen is added to the medium the release of PGE2 
decreases, suggesting that COX is being inhibited. The same tendency is observed when comparing 
the effect of ibuprofen‐loaded fibres and non‐loaded fibres (Figure 6), although none of the 
differences achieved statistical significance. In terms of inhibition, considering the mean values, 
when ibuprofen is added in solution there is a 56% decrease in PGE2 release, while ibuprofen released 
from P(TMC‐CL) electrospun fibres can reduce the release of PGE2 by 47%. However, when 
comparing the effect of ibuprofen released from P(TMC‐CL) fibres directly with control conditions 
one should take into account that the amount of drug that can be released from P(TMC‐CL) fibres is 
in a concentration range and can slightly differ from the control concentration used in this assay.  
The effect of ibuprofen on the release of IL‐6, IL‐10 and TNFα was also evaluated. Under the 
experimental conditions of this study, ibuprofen was found to induce no significant effect on the 
release of IL‐6 or IL‐10 when added in solution or when released from electrospun P(TMC‐CL) fibres 
(Figure 6). The concentration of TNFα secreted into the cell culture medium was found to be below 
the detection limit (3.5 pg/ml) of the ELISA assay (data not shown).  
4 Discussion 
The preparation of nerve conduits by electrospinning holds the promise of allowing easy preparation 
of fibres, at the nanometre scale, that can guide axonal growth and be loaded with biologically active 
molecules able to enhance nerve regeneration processes (Lee and Arinzeh, 2011). In the present 
work, the aim was to prepare fibres of a statistical copolymer of TMC and CL with low TMC content 
(11 mol%) by electrospinning and to load these with an anti‐inflammatory drug. The idea beyond this 
strategy is to design scaffolds that can provide physical support for nerve cell growth, and that 
simultaneously minimize, at the lesion site, the inflammatory reaction that could counteract nerve 
regeneration. The preparation of electrospun structures based on a block copolymer of TMC and CL 
(Jia et al., 2006) or blends of P(TMC) and P(CL) (Han et al., 2010) have been reported in the literature. 
Nevertheless, a statistical copolymer holds the advantage of reducing the formation of crystalline 
domains and reducing phase separation within the polymer structure, which is desirable when 
envisaging the use of these materials in implantable devices (Pêgo et al., 2001). The authors have 
previously reported on the use of selected statistical P(TMC‐CL) for the preparation of microporous 
and macroporous conduits for nerve reconstruction in the peripheral nervous system. P(TMC‐CL) 
with a high CL content has been shown to possess adequate mechanical properties and degradation 
rate to be used in a nerve regeneration strategy (Pêgo et al., 2001, 2003), as it is able to support nerve 
regeneration in vivo (Vleggeert‐Lankamp et al., 2008). This paper describes for the first time the 
preparation of electrospun fibres from this copolymer.  
By using different DCM–DMF mixtures in the electrospinning solution it was possible to prepare 
fibrous meshes with variable mean fibre diameter. Increasing the DMF content in solution, mean fibre 
diameter was decreased from 1.09 µm to 0.48 µm. DMF is a high conductivity solvent, and its use in 
the preparation of solutions for electrospinning leads to an increase in jet splaying and a reduction of 
fibre diameter (Hsu and Shivkumar, 2004). Typically, DMF is used below 30% in solution, as described 
for the preparation of fibres of P(CL) (Bölgen et al., 2005) and P(CL)/P(TMC) blends (Han et al., 2010). 
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Herein, the preparation of fibres from solutions containing up to 50% of DMF was explored. Results 
show that by increasing the DMF content one can obtain very homogeneous fibre meshes, with 
narrower fibre diameter distribution and smaller mean fibre diameter. However, the use of 1:1 DCM–
DMF solutions was revealed to be unsuitable for the preparation of ibuprofen‐loaded P(TMC‐CL) 
fibres at the drug concentrations tested. It was previously described that the incorporation of drugs 
in electrospinning solutions can lead to an increase in solution conductivity (Kim et al., 2004). This 
increase, combined with the high DMF content, may cause fibres to bind together because of the 
high conductivity (Heikkilä and Harlin, 2008) and high boiling point of DMF, which prevent solvent 
evaporation during fibre deposition (Hsu and Shivkumar, 2004).  
Ibuprofen‐loaded fibres were obtained from 1:0, 6:1 and 3:1 DCM–DMF mixtures. In terms of 
morphology, when applying a 5% of ibuprofen (w/w of polymer) load, a tendency towards a decrease 
in mean fibre diameter is observed compared with unloaded fibres. This effect is particularly 
noticeable for 1:0 DCM–DMF solutions, probably because the presence of the drug led to a more 
marked increase in solution conductivity compared with solutions containing DMF (Kim et al., 2004). 
Although the differences in terms of mean fibre diameter are not significant, when loading 10% 
ibuprofen in solution, jet stability and solvent evaporation are reduced, the latter being particularly 
evident in the case of the 3:1 DCM–DMF solution. The increase in jet instability with higher drug 
loading has also been reported previously (Natu et al., 2010).  
The presence of ibuprofen in P(TMC‐CL) fibres was clearly demonstrated by ATR‐FTIR and Raman 
spectroscopy. Both techniques showed that the chemical stability of ibuprofen is maintained after 
electrospinning. In addition, no alterations in the characteristic peaks of P(TMC‐CL) and ibuprofen 
are seen in ibuprofen‐loaded P(TMC‐CL) spectrum, indicating that there is no significant chemical 
interaction between the polymer and the drug, as previously observed in ibuprofen‐loaded cellulose 
acetate fibres (Tungprapa et al., 2007).  
The ibuprofen release kinetics from P(TMC‐CL) fibres were assessed in physiological medium (PBS, 
37 °C). Results demonstrate that ibuprofen is released within the first 24 h after incubation in PBS, 
independently of the solvent mixture used for the preparation of the fibres. It was previously reported 
that the expression of cycloxygenase‐2 peaks 3 h after spinal cord injury (SCI), and is maintained for 
3 days (Adachi et al., 2005). In this context, the release of ibuprofen in the early hours after the lesion 
can provide the expected therapeutic benefit. A complete ibuprofen release in the first 24 h of 
incubation under physiological conditions has also been reported using cellulose acetate fibres 
(Tungprapa et al., 2007). In terms of kinetics, we found an initial burst release for fibres prepared from 
6:1 and 3:1 DCM–DMF mixtures. However, in the case of fibres prepared from 1:0 DCM–DMF the 
release was found to be diffusion dependent, as it fits the Higuchi model for drug release (Siepmann 
and Peppas, 2001). Indeed, the cumulative amount of ibuprofen correlates with the square root of 
the time (R2 > 0.94) for the first 8 h of incubation for fibres prepared from 1:0 DCM–DMF solutions. 
Conversely, no linearity was observed for ibuprofen release from P(TMC‐CL) fibres prepared from the 
3:1 and 6:1 DCM–DMF solutions. It was hypothesized that the presence of DMF in solution could 
affect the drug distribution within the fibre, leading to a burst release compared with fibres prepared 
from solutions without DMF. To address this point samples were analyzed using confocal Raman 
microscopy. To the best of the authors' knowledge this is the first report using confocal Raman 
microscopy to assess drug distribution in an electrospun fibre. Mapping experiments by confocal 
Raman allowed screening of specific areas within an electrospun fibre. By using a step slightly smaller 
than the theoretical size of the spot of the laser beam (0.7 µm), mapping experiments provided the 
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profiling of all the sample area and discrimination of subtle differences in composition (Adar, 2008). 
The mapping of the drug in P(TMC‐CL) fibres showed that ibuprofen distribution was not completely 
homogenous. Nevertheless, at the spatial resolution offered by the experimental setup used, no 
preferential localization of the drug was identified that could be correlated with the burst release (for 
example, at the fibre edge). In addition, no significant differences were detected when comparing 
fibres prepared from 1:0 and 3:1 DCM–DMF solutions, suggesting that, at the submicrometer scale, 
the drug distribution is independent of the solvent mixture applied during electrospinning. The 
results indicate that other parameters are probably playing a role in ibuprofen release, for example 
the fibre diameter (Cui et al., 2006). Although no significant differences were detected in terms of 
mean fibre diameter, the fibre diameter distribution was different between these two types of 
samples. In fibres prepared from 1:0 DCM–DMF mixtures the presence of a small percentage of fibres 
with a large diameter (> 3 µm) was observed and could have contributed to delaying the release of 
the drug by increasing the drug diffusion pathway within the polymeric fibre structure.  
Owing to the important role of macrophages as effectors of an inflammatory response and as these 
cells are targets of ibuprofen, primary human monocyte‐derived macrophages were selected to 
evaluate ibuprofen bioactivity after the release from electrospun fibres. Macrophages are highly 
dynamic and versatile cells, and their response to exogenous stimuli is generally accompanied by 
alterations in actin assembly/disassembly and cell morphology. These alterations may occur as a 
consequence of a number of effects such as surface topography (Cao et al., 2010), drugs (Chiou et al., 
2003) or soluble factors (Shinji et al., 1991; Porcheray et al., 2005). Thus, the effect of ibuprofen‐
loaded P(TMC‐CL) fibres on macrophage morphology was investigated by observing the distribution 
patterns of cytoskeleton proteins (α‐tubulin and F‐actin). The results show no major alterations of 
actin/tubulin cytoskeleton organization in macrophages incubated with ibuprofen or ibuprofen‐
loaded P(TMC‐CL) fibres. However, it cannot be excluded that, to be perceived, considerable 
alterations would need to have occurred in the heterogeneous macrophage cell population under 
study. Cells incubated with ibuprofen‐loaded P(TMC‐CL) fibres secreted less PGE2 into the cell 
culture medium than did non‐loaded fibres. Although the result did not accomplish the statistical 
significance (p = 0.06) because of the high variability between cell donors, this result strongly 
suggests that the drug incorporated in the electrospun fibres retains its bioactivity. This result is 
reinforced by the fact that the percentage of inhibition obtained (47%) is similar to that found with 
treatment with ibuprofen in solution (56%).  
In addition to the classical view of ibuprofen activity, acting on the prostaglandin pathway, there is 
mounting evidence that lowering levels of eicosanoids is not the only mechanism by which ibuprofen 
exerts its effects (Stuhlmeier et al., 1999; Zhou et al., 2003). Stuhlmeier and co‐workers (1999) 
showed that ibuprofen can inhibit the nuclear translocation of the nuclear factor kappa B (NF‐kB), a 
transcription factor critical for the upregulation of expression of pro‐inflammatory genes. These 
reports prompted evaluation of the concentration of pro‐inflammatory cytokines (TNFα and IL‐6) 
and an anti‐inflammatory cytokine (IL–10) in the cell culture medium in this study. Under the 
experimental conditions applied in this study, no significant levels of TNFα were found in the cell 
culture medium. For IL‐6 and IL‐10, no major differences were found when comparing cytokine levels 
secreted by cells incubated with ibuprofen‐loaded P(TMC‐CL) fibres or non‐loaded fibres. Similar 
results were obtained when cells were treated with ibuprofen in the medium (0.1 mg/ml), suggesting 
that under the set conditions the drug exerts no effect on the cytokine release profile. In the literature 
divergent effects on cytokine release are ascribed to ibuprofen. Some authors have shown that 
ibuprofen induces a decrease in the secretion of TNFα and IL‐1β by mononuclear cells (Stuhlmeier et 
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al., 1999; Lamanna et al., 2012), whereas a concentration‐dependent increase of TNFα and IL‐6 has 
been observed by others (Sirota et al., 2001; Lee and Chuang, 2010). Recently, Lamanna and 
colleagues (2012) reported the inhibition of TNFα secretion by a macrophage cell line when cells were 
incubated with a high concentration of ibuprofen (1 mg/ml). However, when applying this 
concentration, the authors (Lamanna et al., 2012) also found ibuprofen‐mediated cytotoxicity and, 
in agreement with the results of the present study, incubating cells with 0.1 mg/ml of ibuprofen was 
found to have no effect on IL‐6 and TNFα release into the culture medium.  
5 Conclusions 
Fibres from P(TMC‐CL) were successfully prepared by electrospinning. It is shown here that by 
adjusting the solvent composition, one can change the mean fibre diameter in a controlled manner. 
An anti‐inflammatory drug can be loaded in P(TMC‐CL) fibres, the release kinetics being dependent 
on fibre morphology, which is tuned by the solvent mixture applied for preparation of the 
electrospinning solution. Ibuprofen was found to maintain its chemical stability and bioactivity after 
electrospinning, as demonstrated by the fact that the drug was able to reduce the amount of PGE2 
secreted into the cell culture medium by human macrophages. The use of confocal Raman 
microscopy as a mean to assess the drug distribution within electrospun fibres is also proposed for 
the first time, being a promising technique to provide new cues on the drug‐release process.  
The results provide an important insight into the design of a P(TMC‐CL)‐based nerve conduit 
combining physical cues provided by the fibres with an anti‐inflammatory signalling molecule, which, 
together, can assist nerve regeneration. 
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Figure 1. Representative scanning electron microscopy photomicrographs of poly(trimethylene carbonate‐co‐ε‐
caprolactone) [P(TMC‐CL)] fibres and fibre diameter distribution (n = 3). Samples were prepared using P(TMC‐CL) 
solutions in a dichloromethane (DCM)–N,N‐dimethylformamide (DMF) mixture with increasing amounts of DMF: 
(A) 1:0 DCM–DMF; (B) 6:1 DCM–DMF; (C) 3:1 DCM–DMF; (D) 1:1 DCM–DMF. Higher magnification images scale 
bar = 20 µm 
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Figure 2. Scanning electron microscopy photomicrographs of ibuprofen‐loaded poly(trimethylene carbonate‐co‐
ε‐caprolactone) [P(TMC‐CL)] fibres and respective fibre diameter distribution (n = 3). Fibres were obtained from 
solutions containing 5% (A–D) and 10% (E–G) of ibuprofen (w/w of polymer) and applying different 
dichloromethane (DCM)–N,N‐dimethylformamide (DMF) mixtures as solvent: (A,E) 1:0 DCM–DMF; (B,F) 6:1 DCM–
DMF; (C,G) 3:1 DCM–DMF; (D) 1:1 DCM–DMF. Higher magnification images scale bar = 20 µm 
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Figure 3. (A) Attenuated total reflectance–Fourier transform infrared spectroscopy spectrum of ibuprofen‐loaded 
poly(trimethylene carbonate‐co‐ε‐caprolactone) [P(TMC‐CL)] fibres prepared from 1:0 dichloromethane (DCM)–
N,N‐dimethylformamide (DMF) solutions (pink). The spectra of ibuprofen (in green) and non‐loaded fibres (blue) is 
shown for comparison. Curve fitting in the spectral region between 1670/cm and 1800/cm of (I) P(TMC‐CL) fibres 
and (II) ibuprofen‐loaded P(TMC‐CL) fibres. (B) Raman spectra of ibuprofen (dark blue), P(TMC‐CL) fibres (green), 
and ibuprofen‐loaded P(TMC‐CL) fibres (light blue) obtained from 1:0 DCM–DMF solutions. (C,D) Confocal Raman 
microscopy analysis of ibuprofen‐loaded P(TMC‐CL) fibres. (I) In images blue indicates the region analysed from 
ibuprofen‐loaded P(TMC‐CL) fibres prepared from (C) 1:0 DCM–DMF and (D) 3:1 DCM–DMF solutions, respectively 
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(axis indicates distance in µm). (II) For each sample the mapping of the 1610/cm ibuprofen Raman band relative to 
background bands (1510–1525/cm and 1645–1665/cm; axis indicates distance in µm) is presented. These are 
representative images from three different areas analysed. The overlay of the spectra obtained for each point is 
presented in Figure S3 (see Supporting Information). Regions with high concentration of ibuprofen are depicted in 
bright green (*) and regions with lower concentration are depicted in dark green (+). (E) Representative spectra of 
these regions are shown 
 
Figure 4. Cumulative release of ibuprofen from poly(trimethylene carbonate‐co‐ε‐caprolactone) [P(TMC‐CL)] 
fibres in phosphate‐buffered saline (PBS) (37 °C). Samples were prepared from (A) 1:0 dichloromethane (DCM)–
N,N‐dimethylformamide (DMF), (B) 6:1 DCM–DMF and (C) 3:1 DCM–DMF solutions containing 5% ibuprofen (w/w 
of polymer). Fibre concentration in PBS was 5 mg/ml (n = 9) 
 
Figure 5. (A) Macrophage viability when incubated for 72 h with ibuprofen at different concentrations. The 
percentage of viable cells was calculated relative to cells treated with ibuprofen solvent (ethanol 70% v/v). Bars 
represent mean values and error bars show standard deviation. Results are representative of three independent 
experiments. (B–E) Actin–tubulin cytoskeleton immunolabelling of macrophages. Macrophages were incubated 
for 72 h in the presence of (B) ethanol 70% (v/v), (C) ibuprofen 0.1 mg/ml, (D) poly(trimethylene carbonate‐co‐ε‐
caprolactone) [P(TMC‐CL)] fibres, and (E) ibuprofen‐loaded P(TMC‐CL) fibres. Scale bar = 100 µm. α‐Tubulin is 
shown in red, F‐actin in green and the cell nucleus in blue. Magnified images of each condition are also presented 
(scale bar = 20 µm) 
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Figure 6. Effect of ibuprofen on (A) prostaglandin E2 (PGE2) and (B) cytokine [interleukin (IL)‐6 and IL‐10] release 
by human macrophages. Results are expressed as box‐whisker plots showing the quantification of (A) PGE2 or (B) 
IL‐6 and IL‐10 released into the cell culture medium after 72 h in contact with soluble ibuprofen added in solution 
to the cell culture medium or released from P(TMC‐CL) electrospun fibres. The P(TMC‐CL) fibres were prepared 
from 1:0 dichloromethane (DCM)–N,N‐dimethylformamide (DMF) solutions. Cells incubated with non‐loaded 
fibres (Fibre) or with ibuprofen (IBU) solvent (ethanol 70% v/v, Control) were used as controls. Results were 
obtained from cells from five independent donors and seven samples and are normalized by the total amount of 
protein in the supernatant. The p‐value calculated by t‐test 
 
Table 1. Poly(trimethylene carbonate‐co‐ε‐caprolactone) [P(TMC‐CL)] electrospun fibre diameters 
 
Fibre diameter (µm) 
1:0 DCM–DMF 6:1 DCM–DMF DCM:DMF (3:1) 1:1 DCM–DMF 
Non‐loaded 1.09 ± 0.10 1.02 ± 0.19 0.67 ± 0.12 0.48 ± 0.03 
Ibuprofen 5% 0.84 ± 0.08 0.91 ± 0.09 0.76 ± 0.06 – 
Ibuprofen 10% 1.2 ± 0.05 0.91 ± 0.2 0.84 ± 0.12 – 
Mean diameter ± standard deviation (n = 3) of P(TMC‐CL) fibres prepared from dichloromethane (DCM)–N,N‐
dimethylformamide (DMF) solutions at ratios of 1:0, 6:1, 3:1 and 1:1 in the absence or presence of 5% and 10% of 
ibuprofen (w/w of polymer), respectively. Standard deviation represents variability between different samples. 
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Supporting Information  
Figure S1. 1H NMR spectrum of ibuprofen-loaded P(TMC-CL) fibers, showing the identification of ibuprofen 
characteristic peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Full ATR-FTIR spectrum of ibuprofen (grey), ibuprofen-loaded P(TMC-CL) fibers (black) and P(TMC-CL) 
(red).   
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Figure S3. Overlay of spectra obtained from mapping experiments of ibuprofen-loaded P(TMC-CL) fibers 
prepared from (A) DCM:DMF (1:0) and (B) DCM:DMF (3:1) solutions. 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Standard calibration curve obtained for ibuprofen. 
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Figure S5. Fittings according to Higuchi model for drug release for fibers prepared from (A) DCM:DMF (1:0), (B) 
DCM:DMF (6:1) and (C) DCM:DMF (3:1) 
 
Figure S6. SEM micrographs of ibuprofen-loaded P(TMC-CL) fibers prepared from DCM:DMF (1:0) solution (A) 
before and (B) after ibuprofen release.  
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